Navigation Links
New Revolutionary Femoral Access Site Closure Device Shows Unparalleled Efficacy, Safety & Ease of Use, in a Wide Range of Patients Including Patients With a Challenging Anatomy
Date:5/1/2012

CAESAREA, Israel, May 1, 2012 /PRNewswire/ --

CardioDex announces initial commercial use of a groundbreaking femoral access site closure device. Recent data from commercial use of the device on 41 patients at St Marien Hospital in Siegen Germany showed 100% success rate and no complications. "We are very excited about these new data that demonstrates that this device provides a viable treatment for a major unmet medical need due to the increasing use worldwide of percutaneous femoral access and the subsequent high rate of complications seen" said Dr. Hans Peter Hobbach, Deputy Chief of St Marien Hospital cardiac catheterization laboratory.

The new CardioDex thermal femoral artery closure device was used in 25 diagnostic cases and 16 interventional cases. The 100% success rate was obtained for normal or diseased femoral vessels with calcified plaque. According to Dr Shimon Eckhouse, Chairman and founder of CardioDex Ltd., "These very positive results confirm the data we observed in the first single-center clinical trial, that were presented earlier this year. This demonstrated performance of the Cardiodex closure device opens the door to a whole new and long awaited era for femoral arterial access and closure." One of the most exciting features of the device is the extremely short period before patient ambulation, diagnostic patients were ambulated within 2 hours and PCI (Percutaneous Coronary Intervention) patients were ambulated within 4 hours. There were no cases of hematoma or late bleeding, despite the fact that PCI patients were fully anticoagulated with heparin, aspirin and clopidogrel. Neither were there any cases of post procedural discomfort.

Method of action

The mechanism of action of the CardioDex device is based on controlled thermal closure of the arterial puncture site. The device consists of a temporary Nitinol anchor which is delivered via an existing introducer sheath and used to locate the puncture site. ,. The fully controlled heating step is made possible by an integrated battery power unit and a heating system that is inserted over the Nitinol anchor wire on the site of the arteriotomy. Local short heating pulses provide sufficient hemostasis through the cross linking of collagen, leaving no residual material at the puncture site.

Unmet medical need

The market for percutaneous femoral access and vascular closure devices has grown significantly since they were first launched in the early 1990's and is based on a wide range of technologies. While some of the newer closure devices can be used in what was considered to be patients at high risk such as those with PAD (Peripheral Arterial Disease) and smaller caliber arteries, the CardioDex device can be used in all types of patients and situations, including bifurcations, PAD, SFA (superficial femoral arterial) punctures as well as in very thin or obese patients. Whatever the anatomic challenge, the CardioDex device has consistently shown outstanding efficacy, short time to ambulation and reliable closures free of residual materials.

Professor Charles Davidson, Clinical Chief, Cardiology Medical Director, Bluhm Cardiovascular Institute Northwestern Memorial Hospital and CardioDex's Chief medical officer states that:  "Thermal closure of the arterial puncture site has several potential advantages including nothing left behind and the ability to address challenging anatomies.  The initial successful cases we have had demonstrate the promise of this new technology".

About CardioDex

CardioDex (http://www.cardiodex.com) was founded by one of the most renowned medical entrepreneurs in the health and aesthetic medicine arena, Dr. Shimon Eckhouse, a scientist with broad experience in medical devices and medical technology.

CardioDex, Ltd. develops and manufactures an innovative disposable solution for the closure of arterial access sites following endovascular catheterization procedures. The Company also owns a rich intellectual proprietary portfolio and a strong and concrete IP coverage of its current and future technology applications.

Media contact:
Burson-Marsteller
Linda Pavy
Tel. +33-1-41-86-76-26
Tel. +33-6-07-59-43-95
e-mail: linda.pavy@bm.com



'/>"/>
SOURCE CardioDex Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Revolutionary New In-Office EVOLVE(R) Laser Prostate Treatment Available Throughout Western Oregon
2. FDA Approves Orphan Drug Status for Revolutionary Cancer Drug for Children
3. Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask
4. BioNanomatrixs Revolutionary Whole Genome Analysis Platform Named to MIT Technology Reviews Annual 10 Emerging Technologies List
5. Z Therapy Is The First In North Texas To Offer Revolutionary Treatment Option For Neck Pain Sufferers
6. Accuri Cytometers Adds Automation to Its Revolutionary C6 Flow Cytometer(R) System With Commercial Launch of CSampler(TM)
7. ForteBio Launches Two Revolutionary High-Throughput, Label-Free Instruments: The Octet(R) RED384 and the Octet QK384
8. Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
9. Microfluidics and POWREX Launch Revolutionary Continuous Pharmaceutical Manufacturing Technology in Japan
10. A revolutionary breakthrough in terahertz remote sensing
11. A revolutionary breakthrough in terahertz remote sensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Symic Bio, a biopharmaceutical company ... category of therapeutics, announced today the completion of enrollment ... artery disease. The trial will evaluate the safety and ... the reduction of restenosis following angioplasty. ... for SB-030," said Nathan Bachtell , M.D., Chief ...
(Date:2/24/2017)... Feb. 24, 2017 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced its unaudited financial results for the third quarter ... December 31, 2016. Third Quarter of Fiscal ... quarter of fiscal 2017 increased by 18.6% to RMB200.9 ...
(Date:2/24/2017)... Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a ... its financial results for the fourth quarter and fiscal year ... Total sales in the fourth quarter ... by 13.6% in USD terms to $77.6 million from $68.3 ... Gross profit increased by 13.3% to $46.8 million from $41.3 ...
(Date:2/24/2017)...  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company ... Opinion Leader event to highlight new clinical data that ... at the upcoming 2017 ASCO-SITC Immuno-Oncology Symposium and the ... held in-person and via live webcast on Tuesday, February ... at the Lotte New York Palace Hotel in ...
Breaking Biology Technology:
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... by 2021 from $8.3 billion in 2016 at a ... to 2021. Report Includes - An overview of ... market trends, with data from 2015 and 2016, and ... - Segmentation of the market on the basis of ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
Breaking Biology News(10 mins):